Although germline variants in MMR genes are rare in breast cancer and the values of these genes are unknown with respect to breast cancer risk, it has been shown that breast cancer carriers of variants in these genes might have worse survival and some of them might benefit from immunotherapy [73]. This evidence concerns the gene MRC1 and breast carcinoma.